Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2012

01-08-2012 | Original Article

Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Authors: Levent Kabasakal, Emre Demirci, Meltem Ocak, Clemens Decristoforo, Ahmet Araman, Yıldız Ozsoy, Ilhami Uslu, Bedii Kanmaz

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2012

Login to get access

Abstract

Purpose

Recent studies have suggested that positron emission tomography (PET) imaging with 68Ga-labelled DOTA-somatostatin analogues (SST) like octreotide and octreotate is useful in diagnosing neuroendocrine tumours (NETs) and has superior value over both CT and planar and single photon emission computed tomography (SPECT) somatostatin receptor scintigraphy (SRS). The aim of the present study was to evaluate the role of 68Ga-DOTA-1-NaI3-octreotide (68Ga-DOTANOC) in patients with SST receptor-expressing tumours and to compare the results of 68Ga-DOTA-D-Phe1-Tyr3-octreotate (68Ga-DOTATATE) in the same patient population.

Methods

Twenty SRS were included in the study. Patients’ age (n = 20) ranged from 25 to 75 years (mean 55.4 ± 12.7 years). There were eight patients with well-differentiated neuroendocrine tumour (WDNET) grade1, eight patients with WDNET grade 2, one patient with poorly differentiated neuroendocrine carcinoma (PDNEC) grade 3 and one patient with mixed adenoneuroendocrine tumour (MANEC). All patients had two consecutive PET studies with 68Ga-DOTATATE and 68Ga-DOTANOC. All images were evaluated visually and maximum standardized uptake values (SUVmax) were also calculated for quantitative evaluation.

Results

On visual evaluation both tracers produced equally excellent image quality and similar body distribution. The physiological uptake sites of pituitary and salivary glands showed higher uptake in 68Ga-DOTATATE images. Liver and spleen uptake values were evaluated as equal. Both 68Ga-DOTATATE and 68Ga-DOTANOC were negative in 6 (30 %) patients and positive in 14 (70 %) patients. In 68Ga-DOTANOC images only 116 of 130 (89 %) lesions could be defined and 14 lesions were missed because of lack of any uptake. SUVmax values of lesions were significantly higher on 68Ga-DOTATATE images.

Conclusion

Our study demonstrated that the images obtained by 68Ga-DOTATATE and 68Ga-DOTANOC have comparable diagnostic accuracy. However, 68Ga-DOTATATE seems to have a higher lesion uptake and may have a potential advantage.
Literature
1.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.PubMedCrossRef
2.
Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997;70:530–7.PubMedCrossRef
3.
Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010;42:220–5.PubMedCrossRef
4.
Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Ejick CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53–73.PubMedCrossRef
5.
Srirajkanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875–82.CrossRef
6.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. Ga68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.PubMedCrossRef
7.
Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan). Mol Imaging Biol 2011;13:583–93.PubMedCrossRef
8.
Frilling A, Sotiropoulos C, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252:850–6.PubMedCrossRef
9.
Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214–21.PubMedCrossRef
10.
Ambrossini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669–73.CrossRef
11.
Pettino C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72–9.CrossRef
12.
Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis fort he preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870–5.PubMedCrossRef
13.
Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010;31:1025–32.PubMed
14.
Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 2010;54:61–7.PubMed
15.
Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26:963–70.PubMedCrossRef
16.
Campana D, Ambrossini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010;51:353–9.PubMedCrossRef
17.
Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48–52.PubMedCrossRef
18.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef
19.
Wild D, Schmitt JS, Ginj M, Mäcke H, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRef
20.
Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.PubMedCrossRef
21.
Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52–60.PubMedCrossRef
22.
Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011;38:1659–68.PubMedCrossRef
23.
Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 2006;13:52–60.PubMed
24.
Basu S, Abhyankar A, Kand P, Kumar R, Asopa R, Rajan MG, et al. ‘Reverse discordance’ between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs. Nucl Med Commun 2011;32:654–8.PubMedCrossRef
Metadata
Title
Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours
Authors
Levent Kabasakal
Emre Demirci
Meltem Ocak
Clemens Decristoforo
Ahmet Araman
Yıldız Ozsoy
Ilhami Uslu
Bedii Kanmaz
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2123-y

Other articles of this Issue 8/2012

European Journal of Nuclear Medicine and Molecular Imaging 8/2012 Go to the issue

Short Communication

PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma

Image of the Month

Acute intramural haematoma of the ascending aorta

Letter to the Editor

131I gastric uptake with and without omeprazole in patients undergoing radioiodine therapy for differentiated thyroid carcinoma

Original Article

Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution

Original Article

Parametric imaging of myocardial viability using 15O-labelled water and PET/CT: comparison with late gadolinium-enhanced CMR

Book Review

Francis A. Burgener, Christopher Herzog, Steven P. Meyers, Wolfgang Zaunbauer (eds): Differential Diagnosis in Computed Tomography (2nd edition)